Announcements Trials
Browse Landscape

Phase

Phase 2 46Phase 1 11Phase 1/2 6Phase NA 2Phase 4 2Phase 2/3 2Phase 3 1

Status

Completed 3Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 6INDUSTRY 6NIH 3NETWORK 1

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 5CNS 1

Conditions

Melanoma 5Glioma 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × dabrafenib × Clear all
NCT06712875 2025-05-29

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Ann & Robert H Lurie Children's Hospital of Chicago

Phase 1/2 Recruiting
27 enrolled
CNS

Glioma

NCT02872259 2025-01-14

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Haukeland University Hospital

Phase 1/2 Completed
74 enrolled
Dermatologic

Melanoma

NCT02392871 2024-11-27

CombiRT

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Completed
10 enrolled
Dermatologic

Melanoma

NCT03455764 2024-07-31

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Dana-Farber Cancer Institute

Phase 1/2 Completed
6 enrolled 12 charts
Dermatologic

Melanoma

NCT02143050 2023-11-18

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

University of Louisville

Phase 1/2 Withdrawn
Dermatologic

Melanoma

NCT03754179 2021-04-28

COMBI-R2

Universitair Ziekenhuis Brussel

Phase 1/2 Unknown
63 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡